Fig. 6

The responses to strictosamide (1) and mitraphylline (2) were evaluated in cells exposed α4β1 agonist. (A) Chemical structure of the α4β1 agonist molecule. (B) Cell viability in ITGA4 agonist treated in AGS cells. Cells were treated with α4β1 agonist for 48 h with indicated concentration. (C) Relative mRNA levels of N-cadherin, ITGA4 and FAK, after treatment with strictosamide (1) and mitraphylline (2) for 48 h in AGS cells. (D) Representative images of each insert and relative number of invaded cells in the Transwell invasion assay. AGS cells were treated with strictosamide (1) and mitraphylline (2) at concentrations of 1 and 2.5 µM for 24 h. The α4β1 agonist was treated at a concentration of 2.5 µM. Data are presented as mean ± S.D. Statistical significance was determined as follows: *p < 0.05, **p < 0.01, ***p < 0.001, NS: not significant (p > 0.05) compared to DMSO-treated cells; #p < 0.05, ##p < 0.01, ###p < 0.001, NS: not significant (p > 0.05) compared to α4β1 agonist-treated cells; @p < 0.05, @@p < 0.01, @@@p < 0.001, NS: not significant (p > 0.05) compared to strictosamide (1)- or mitraphylline (2)-treated cells.